ABCIXIMAB

ABCIXIMAB

BRAND NAME:- REOPRO 2mg /ml inj .

ABCIXIMAB is nonantigenic ,antiplatelet and antithrombotic drugs . These are the drug which interfere with platelet function and are useful in the prophylaxis of thromboembolic disorders.

PHARMACOLOGICAL & MECHANISM OF ACTION:-

It is the Fab fragment of a chimeric monoclonal antibody against GPIIb/IIIa, protein,but is relatively nonspecific and binds to some other surface proteins as well. Given along with Aspirin+ heparin during PCI it has markedly reduced the incidence of restenosis, subsequent MI and death. In the ISAR-REACT2 trial addition of ABCIXIMAB to clopidogrel(600mg oral loading dose) for PCI in high risk ACS patients, reduced ischaemic events by 25%. After a bolus dose, platelet aggregation remain inhibited for 12-24hr, while the remaining antibody is cleared from blood with a t½ of 10-30min.

PRECAUTIONS:-

ABCIXIMAB is nonantigenic. The main risk haemorrhage, incidence of which can be reduced by carefully managing the concomitant heparin therapy. Thrombocytopenia is another complication. It should not be used second time ,since risk of thrombocytopenia increases . Constipation, ileus and arrhythmias can occur. It is expensive, but is being used in unstable angina and as adjuvant to  coronary thrombolysis /PCI with stent placement.

DOSE:-0.25mg /kg  i.v . 10-60 min before PCI , followed by 10 ug / min  for 12hr.

USED:- use as a coronary artery disease, Acute coronary syndrome (ACSs),cerebrovascular disease, prosthetic heart valve and arteriovenous shunts, venous thromboembolism and peripheral vascular disease etc.